{"organizations": [], "uuid": "07942d9c5e8e82f3fc37846c395b74a3a9ddc03f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/22/globe-newswire-oncomed-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-operational-highlights-on-march.html", "country": "US", "domain_rank": 767, "title": "OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-23T00:02:00.000+02:00", "replies_count": 0, "uuid": "07942d9c5e8e82f3fc37846c395b74a3a9ddc03f"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/22/globe-newswire-oncomed-pharmaceuticals-to-report-fourth-quarter-and-full-year-2017-financial-results-and-operational-highlights-on-march.html", "ord_in_thread": 0, "title": "OncoMed Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights on March 8th, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "redwood city", "sentiment": "none"}, {"name": "calif.", "sentiment": "none"}], "organizations": [{"name": "oncomed pharmaceuticals", "sentiment": "neutral"}, {"name": "oncomed pharmaceuticals, inc.", "sentiment": "neutral"}, {"name": "company", "sentiment": "none"}, {"name": "oncomed pharmaceuticals oncomed pharmaceuticals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "REDWOOD CITY, Calif., OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report fourth quarter and full year 2017 financial results and operational highlights on Thursday, March 8th, 2018. OncoMed management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).\nAnalysts and investors can participate in the conference call by dialing (855) 420-0692 (domestic) and (484) 756-4194 (international) using the conference ID# 4997704. The webcast of the conference call can be accessed live on the Investor Relations section of the OncoMed website, http://www.oncomed.com , and will be available for replay through June 30th, 2018.\nAn audio replay of the conference call can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) utilizing the conference ID number listed above.\nAbout OncoMed Pharmaceuticals\nOncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP131-R10) and anti-TIGIT (OMP-313M32) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com .\nInvestor Relations Contact:\nPeter Rahmer\nTrout Group\nprahmer@troutgroup.com\n(646) 378-2973\nMike Zanoni\nTrout Group\nmzanoni@troutgroup.com\n(646) 378-2924\nSource:OncoMed Pharmaceuticals, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=NcbWntmyHqjzUskHZCTUbM_o3dKq9MS6RpS5fgU0OExNNGdVDDc_nD63wozDo3HyDT-W-c28N5TgRTaIOMXIdA==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/250c7064-4e3c-489e-ae1b-9daf1a471d06", "https://www.globenewswire.com/Tracker?data=by0yrhyDeTXk8pxjTr3rkVl2nSGhQDg6EGrcc5G8hmVhCCdeOneB06iXfKDEVdwd5nVyH4jmrkkP4uJkLMkxDi4KKTZa45Uufqtl2VB-2VW4bEBAuEvxu9Ht6QD4vm9EjQ6se7SH9F2wDDY20QRF4o7zdwUHCjfTS1j3xf7TBaAPQrYmQM6Y5VHr1oK566GrEjnFXjwBnZSRQmcKYH8jo9bs2CBbEpsf78KtpiJf_sjhLHBVJZomF3BkcbIAe0hi4FRJaF8WWKIySarJMVQiIQ=="], "published": "2018-02-23T00:02:00.000+02:00", "crawled": "2018-02-23T01:52:22.009+02:00", "highlightTitle": ""}